• 1997–2004 Ph.D., University of Chicago

• 1992–1995 M.Sc., Peking University Health Science Center

• 1988–1992 B.Sc., Anhui University

• 2023–Present

Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University

Institute of Translational Medicine, Shanghai Jiao Tong University

• 2018–2022

Shanghai Ruijin Hospital

Engaged in innovative drug discovery and skin biology research, with a focus on developing protein kinase inhibitors as chemical probes to decode cellular signaling networks, investigate mechanisms of tumor drug resistance, and explore the natural evolution and aging of skin stem cells.

• 2013–2017

Massachusetts General Hospital, Harvard Medical School

• 2006–2012

Dana-Farber Cancer Institute, Harvard Medical School

• 2004–2005

Department of Biology, Massachusetts Institute of Technology (MIT)

• Published 86 papers in high-impact journals such as Nature and Cancer Research

• Total citations: 13,800+ | H-index: 41

• Holds 6 international patents

• Discovered widely used research compounds such as GNF-5 and Torin1

• Major contributor to the development of the allosteric BCR-ABL inhibitor Asciminib (Novartis), a breakthrough drug for chronic myeloid leukemia

• Currently leading the development of 4th-generation EGFR inhibitors, which entered clinical trials in 2022

• Supported by major grants from the National Natural Science Foundation of China (NSFC), Shanghai Science and Technology Committee, and pharmaceutical industry collaborations

• Li Y, Zhu T, Yang J, Zhang Q, Xu S, Ge S, Jia R*, Zhang J*, Fan X.* EHMT2 promotes tumorigenesis in GNAQ/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway. Acta Pharm Sin B. 2024;14(3):1187-1203

• Li Y, Yang J, Zhang Q, Xu S, Sun W, Ge S, Xu X, Jager MJ, Jia R*, Zhang J*, Fan X.* Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. Oncogene. 2022;41(27):3539-3553

• Zhang Y, Zhang B, Li Y, Dai Y, Li J, Li D, Xia Z, Zhang J, Liu P, Chen M, Jiao B, Ren R. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma. Front Med. 2022;16(5):784-798

• Yang J, Li Y, Zong C, Zhang Q, Ge S, Ma L, Fan J, Zhang J*, Jia R*. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle. Invest. Ophthalmol. & Vis. Sci. 2021:62 (15):11

• Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R, Fan X. Uveal melanoma: progress in molecular biology and therapeutics. Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852